Teva leader to exit company in May, former Bristol executive to step in
JERUSALEM — Teva Pharmaceutical Industries announced that Shlomo Yanai, president and CEO, will retire from his post in May.
Yanai, who has served in this capacity for five years, has helped Teva expand from a mainly generics business to a more diversified pharmaceutical company, with expected 2012 revenue of approximately $22 billion, and an expanded footprint in the European, Asian and Latin America markets.
Yanai will be succeeded by former Bristol-Myers Squibb executive Jeremy Levin. At Bristol, Levin direct responsibility for strategy, alliances and transactions, and managed its portfolio of alliances.